Universal Health Services (UHS)
(Delayed Data from NYSE)
$205.26 USD
+0.95 (0.46%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $205.49 +0.23 (0.11%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$205.26 USD
+0.95 (0.46%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $205.49 +0.23 (0.11%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
Zacks News
Masimo (MASI), UCHealth Unite to Improve Care With Telehealth
by Zacks Equity Research
Masimo (MASI) collaborates with UCHealth to boost patient care by combining its latest virtual care technologies with UCHealth's clinical expertise and telehealth innovations.
Is Universal Health Services (UHS) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Boston Scientific (BSX) Completes First Case With Its PFA System
by Zacks Equity Research
Boston Scientific (BSX) announces the completion of its first commercial cases with its FDA-cleared Farapulse PFA System in the United States.
Universal Health Services (UHS) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Universal Health Services (UHS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merit Medical's (MMSI) SCOUT Guidance System Gets FDA Nod
by Zacks Equity Research
Merit Medical's (MMSI) SCOUT MD Surgical Guidance System receives FDA clearance, which aims to boost the treatment of breast cancer by increasing accuracy to target tumor sites.
AngioDynamics (ANGO) Divests Its PICC & Midline Businesses
by Zacks Equity Research
AngioDynamics (ANGO) finalizes its PICC and Midline businesses divestment to Spectrum Vascular to optimize its product portfolio and to focus on strengthening its med tech segment.
Integer Holdings (ITGR) Q4 Earnings and Sales Beat, Margins Up
by Zacks Equity Research
Integer Holdings (ITGR) reports fourth-quarter results, with earnings and revenues beating their respective consensus marks.
Shockwave Medical (SWAV) Q4 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Shockwave Medical's (SWAV) fourth-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.
West Pharmaceutical (WST) Beats on Q4 Earnings, HVP Drives Sales
by Zacks Equity Research
West Pharmaceutical's (WST) fourth-quarter results reflect a strong demand for non-COVID-19 products, especially HVP devices.
Masimo's (MASI) MightySat Pulse Oximeter Receives FDA Approval
by Zacks Equity Research
Masimo's (MASI) MightySat Medical Pulse Oximeter receives FDA clearance, which makes it the first FDA-approved pulse oximeter to be available OTC.
Veeva (VEEV) & Boehringer Partner to Boost Animal Healthcare
by Zacks Equity Research
Veeva (VEEV) collaborates with Boehringer to offer its Veeva Vault Clinical and Veeva Vault RIM applications to improve animals??? healthcare via technological upliftment.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Edwards (EW) Gains From Balanced Core Growth and New Launches
by Zacks Equity Research
Edwards (EW) is demonstrating the strong performance of the SAPIEN 3 Ultra valve in the United States, Europe and Rest of World.
Tandem (TNDM) Broadens Insulin Pumps Line in the U.S. With Mobi
by Zacks Equity Research
Tandem's (TNDM) Mobi is claimed to be the world's smallest durable automated insulin delivery system.
QuidelOrtho (QDEL) Q4 Earnings and Sales Miss, Margins Fall
by Zacks Equity Research
Despite solid performances by the Labs segment and China and Other regions, QuidelOrtho (QDEL) misses earnings and revenue estimates by 41.8% and 6.9%, respectively.
CVS Health (CVS) Gains From Digital Adoption Amid Competition
by Zacks Equity Research
CVS Health (CVS) has been removing barriers to digital adoption and making it easier for customers to access services such as pharmacy refills and advanced scheduling for immunizations online.
GE Healthcare (GEHC), MedQuest Partner to Boost Imaging Field
by Zacks Equity Research
GE Healthcare (GEHC) collaborates with MedQuest to optimize outpatient imaging networks. With AI capabilities from GE Healthcare, MedQuest is likely to provide better solutions in the imaging space.
ResMed (RMD) to Treat Sleep Apnea With New AirCurve 11 Device
by Zacks Equity Research
ResMed's (RMD) new AirCurve11 series incorporates myAir and AirView digital health apps to provide maximum comfort and support during therapy.
Are Investors Undervaluing HCA Healthcare (HCA) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Cooper Companies (COO), Fulgent Unite to Boost Genetic Testing
by Zacks Equity Research
Cooper Companies (COO) collaborates with Fulgent Genetics to boost newborn genetic screenings. CBR by Cooper Surgical is likely to provide a variety of genetic testing options to its families.
Analyzing 3 Healthcare Stocks Poised for Q4 Earnings Beat
by Kaibalya Pravo Dey
Rising patient volumes, admissions, health awareness and technological advancements in the Q4 are likely to have benefited healthcare players like Universal Health (UHS), Alignment Healthcare (ALHC) and Agiliti (AGTI).
Reasons to Retain The Cooper Companies (COO) in Your Portfolio Now
by Zacks Equity Research
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.
Fresenius Medical (FMS) Gets FDA Nod for New Hemodialysis System
by Zacks Equity Research
Fresenius Medical (FMS) receives an FDA nod for its new 5008X Hemodialysis System that aims to provide better dialysis therapy for kidney patients in the United States.
DexCom (DXCM) Beats on Q4 Earnings, Strong CGM Demand Continues
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
Baxter's (BAX) Q4 Earnings Top, Sales Rise on Strong Demand
by Zacks Equity Research
Baxter (BAX) reports better-than-expected fourth-quarter earnings and sales. BAX's fourth-quarter and full-year results reflect solid demand for a range of its medically essential products.